贝达药业9月3日获融资买入8121.18万元，融资余额5.78亿元

Group 1 - On September 3, Benda Pharmaceutical experienced a slight decline of 0.01% with a trading volume of 856 million yuan [1] - The financing data for Benda Pharmaceutical on that day showed a financing purchase amount of 81.21 million yuan and a financing repayment of 109 million yuan, resulting in a net financing outflow of 28 million yuan [1] - As of September 3, the total balance of margin trading for Benda Pharmaceutical was 590 million yuan, with a financing balance of 578 million yuan, accounting for 1.83% of the circulating market value, indicating a high level compared to the past year [1] Group 2 - As of June 30, the number of shareholders for Benda Pharmaceutical reached 32,100, an increase of 9.97% from the previous period, while the average circulating shares per person decreased by 9.08% to 13,064 shares [2] - For the first half of 2025, Benda Pharmaceutical reported a revenue of 1.731 billion yuan, representing a year-on-year growth of 15.37%, while the net profit attributable to the parent company was 140 million yuan, a decrease of 37.53% year-on-year [2] - Since its A-share listing, Benda Pharmaceutical has distributed a total of 669 million yuan in dividends, with 184 million yuan distributed over the past three years [2]